Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma
Status:
Terminated
Trial end date:
2021-01-31
Target enrollment:
Participant gender:
Summary
This research study is studying a cancer vaccine called Dendritic Cell/MM Fusion vaccine
(DC/MM vaccine) in combination with nivolumab, as a possible treatment for multiple myeloma
(MM).
The drugs involved in this study are:
- Dendritic Cell/MM Fusion vaccine (DC/MM vaccine)
- Nivolumab, an immunotherapy drug